The Phase 3b study found that 14% of patients receiving the modified titration experienced ARIA-E, compared to 24% in those on the standard dosing regimen, according to an Oct. 29 news release from the company. The modified approach allows for once-monthly dosing while maintaining amyloid plaque clearance.
Donanemab was approved by the FDA in July under the brand name Kinsula. Eli Lilly plans to discuss the findings with global regulators and may seek a label update for Kinsula, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.